MedTrace Logo

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

NCT03692429 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-11-20

No results posted yet for this study

Summary

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Conditions

  • Unresectable Metastatic Colorectal Cancer

Interventions

DRUG

CYAD-101

Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

DRUG

FOLFOX

5-FU, leucovorin and oxaliplatin

DRUG

FOLFIRI

5-FU, leucovorin and irinotecan

Sponsors & Collaborators

  • Celyad Oncology SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-28
Primary Completion
2021-11-28
Completion
2036-02-17
FDA Drug
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692429 on ClinicalTrials.gov